Targeting BCL-2 regulated apoptosis in cancer

The ability of a cell to undergo mitochondrial apoptosis is governed by pro- and anti-apoptotic members of the BCL-2 protein family. The equilibrium of pro- versus anti-apoptotic BCL-2 proteins ensures appropriate regulation of programmed cell death during development and maintains organismal health...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Kirsteen J., Tait, Stephen W. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990650/
https://www.ncbi.nlm.nih.gov/pubmed/29769323
http://dx.doi.org/10.1098/rsob.180002
_version_ 1783329620731363328
author Campbell, Kirsteen J.
Tait, Stephen W. G.
author_facet Campbell, Kirsteen J.
Tait, Stephen W. G.
author_sort Campbell, Kirsteen J.
collection PubMed
description The ability of a cell to undergo mitochondrial apoptosis is governed by pro- and anti-apoptotic members of the BCL-2 protein family. The equilibrium of pro- versus anti-apoptotic BCL-2 proteins ensures appropriate regulation of programmed cell death during development and maintains organismal health. When unbalanced, the BCL-2 family can act as a barrier to apoptosis and facilitate tumour development and resistance to cancer therapy. Here we discuss the BCL-2 family, their deregulation in cancer and recent pharmaceutical developments to target specific members of this family as cancer therapy.
format Online
Article
Text
id pubmed-5990650
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Royal Society
record_format MEDLINE/PubMed
spelling pubmed-59906502018-06-11 Targeting BCL-2 regulated apoptosis in cancer Campbell, Kirsteen J. Tait, Stephen W. G. Open Biol Review The ability of a cell to undergo mitochondrial apoptosis is governed by pro- and anti-apoptotic members of the BCL-2 protein family. The equilibrium of pro- versus anti-apoptotic BCL-2 proteins ensures appropriate regulation of programmed cell death during development and maintains organismal health. When unbalanced, the BCL-2 family can act as a barrier to apoptosis and facilitate tumour development and resistance to cancer therapy. Here we discuss the BCL-2 family, their deregulation in cancer and recent pharmaceutical developments to target specific members of this family as cancer therapy. The Royal Society 2018-05-16 /pmc/articles/PMC5990650/ /pubmed/29769323 http://dx.doi.org/10.1098/rsob.180002 Text en © 2018 The Authors. http://creativecommons.org/licenses/by/4.0/ Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original author and source are credited.
spellingShingle Review
Campbell, Kirsteen J.
Tait, Stephen W. G.
Targeting BCL-2 regulated apoptosis in cancer
title Targeting BCL-2 regulated apoptosis in cancer
title_full Targeting BCL-2 regulated apoptosis in cancer
title_fullStr Targeting BCL-2 regulated apoptosis in cancer
title_full_unstemmed Targeting BCL-2 regulated apoptosis in cancer
title_short Targeting BCL-2 regulated apoptosis in cancer
title_sort targeting bcl-2 regulated apoptosis in cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990650/
https://www.ncbi.nlm.nih.gov/pubmed/29769323
http://dx.doi.org/10.1098/rsob.180002
work_keys_str_mv AT campbellkirsteenj targetingbcl2regulatedapoptosisincancer
AT taitstephenwg targetingbcl2regulatedapoptosisincancer

Ejemplares similares